Seres Therapeutics, Inc. MCRB
$5.28
-5.04%
at last close
Market Cap$53.04 million
P/E Ratio—
Div Yield—
Volume38.5K
52-Week Range
$4.32$29.98
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $17.00 (+222.0% upside)
Key Stats
- Today's Range
- $5.28 – $5.67
- 50-Day Range
- $4.32 – $8.25
- 52-Week Range
- $4.32 – $29.98
- Volume
- 39K shs
- Average Volume
- 62K shs
- Market Cap
- $53.04 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.54
- Price / Sales
- 28.17
Short Interest
- Short Interest
- 47.82%
- Days to Cover
- 28.86
Financials (TTM)
- Revenue
- $1.88 million
- Net Income
- $-22,463,000
- Net Margin
- -1192.94%
- Return on Equity
- -65.05%
- Debt-to-Equity
- —
About Seres Therapeutics, Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Related Stocks
Compare head-to-head: MCRB vs LLY·MCRB vs JNJ·MCRB vs ABBV·MCRB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.